Trianni licenses humanized model platform to MacroGenics for oncology research

By Maggie Lynch contact

- Last updated on GMT

(Image: Getty/JacobStudio)
(Image: Getty/JacobStudio)

Related tags: models, Model organism, Mouse models, Research and development, R&D, Immune response, License

Trianni to provide MacroGenics with humanized mouse model platform for its mAb therapeutics research.

MacroGenics has licensed The Trianni Mouse, a transgenic mouse R&D platform for the discovery of fully-human monoclonal antibodies (mAb). The agreement with Trianni will support MacroGenics’ discovery programs for mAb therapeutics used in oncology.

Ezio Bonvini, chief scientific officer of MacroGenics, said in a press release, that the company can use the mouse for its molecules that are based on its Fc optimization and multi-specific DART and TRIDENT platforms. Applying antibodies into these molecules MacroGenics can accelerate its candidate development processes.

Trianni’s platform combines human antibody repertoire with wild-type mouse immune responses to target antigens, according to the company.

Trianni did not respond to a request for comment.

In October of 2017, Juno Therapeutics also signed a licensing agreement with Trianni for its mAb platform. Juno used the mouse model to identify full-human binders for conversion to chimeric antigen receptors as part of the company’s engineered T cell programs.

Juno stated at the time that it was to use the program to establish “next-generation CAR-T cells.”

Humanized mouse model systems are not new, but technology is emerging that could improve their use. Recently, scientists at CytoReason developed a mouse to human​ model. The model is a machine-learning platform for human immune system cell-level simulation. 

Related news

Show more

Related products

show more

Has EDC Kept Up With Changes In Clinical Trials?

Has EDC Kept Up With Changes In Clinical Trials?

Oracle Health Sciences | 14-Dec-2020 | Technical / White Paper

In just a few decades, clinical trials have changed dramatically. Twenty years ago, most of the data used in clinical research was entered on paper, but...

Liver Disease Capabilities

Liver Disease Capabilities

Q² Solutions | 01-Oct-2020 | Clinical Study

We integrate therapeutic insights, state-of-the-art technologies, best-in-class methods and quality systems to optimize NAFLD & NASH study design,...

CAR-T Cell Therapy

CAR-T Cell Therapy

Q² Solutions | 01-Sep-2020 | Clinical Study

Cell therapy involves the transfer of genetically altered cells into a patient. As a global central laboratory services organization, we provide testing...

Related suppliers

Follow us

Products

View more

Webinars